

0590
01/31/02

O/PE

Serial Number: 09/977,283A

CRF Processing Date:

2/12/2002

Edited by:

Verified by:

(STIC staff)

Changed a file from non-ASCII to ASCII **ENTERED**

Changed the margins in cases where the sequence text was "wrapped" down to the next line.

Edited a format error in the Current Application Data section, specifically: #3

Edited the Current Application Data section with the actual current number. The number inputted by the applicant was the prior application data; or other _____

Added the mandatory heading and subheadings for "Current Application Data".

Edited the "Number of Sequences" field. The applicant spelled out a number instead of using an integer.

Changed the spelling of a mandatory field (the headings or subheadings), specifically:

Corrected the SEQ ID NO when obviously incorrect. The sequence numbers that were edited were:

Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited:

Corrected subheading placement. All responses must be on the same line as each subheading. If the applicant placed a response below the subheading, this was moved to its appropriate place.

Inserted colons after headings/subheadings. Headings edited included:

Deleted extra, invalid, headings used by an applicant, specifically:

Deleted: non-ASCII "garbage" at the beginning/end of files; secretary initials/filename at end of file; page numbers throughout text; other invalid text, such as _____

Inserted mandatory headings, specifically:

Corrected an obvious error in the response, specifically:

Edited identifiers where upper case is used but lower case is required, or vice versa.

Corrected an error in the Number of Sequences field, specifically:

A "Hard Page Break" code was inserted by the applicant. All occurrences had to be deleted..

Deleted ending stop codon in amino acid sequences and adjusted the "(A)Length:" field accordingly (error due to a PatentIn bug). Sequences corrected: _____

Other: Sequence 11 - aligned around seq. no. 5.



OIPE

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/977,283A

DATE: 02/12/2002
TIME: 10:55:02

Input Set : A:\PTO.AMC.txt
Output Set: N:\CRF3\02122002\I977283A.raw

PS

5 <110> APPLICANT: Reed, Guy L.
 9 <120> TITLE OF INVENTION: Composition and Method for Enhancing Fibrinolysis
 13 <130> FILE REFERENCE: 0609.4320003
 17 <140> CURRENT APPLICATION NUMBER: 09/977,283A
 19 <141> CURRENT FILING DATE: 2001-10-16
 23 <150> PRIOR APPLICATION NUMBER: 08/934,000
 25 <151> PRIOR FILING DATE: 1997-09-19
 29 <150> PRIOR APPLICATION NUMBER: 60/026,356
 31 <151> PRIOR FILING DATE: 1996-09-20
 35 <160> NUMBER OF SEQ ID NOS: 81
 39 <170> SOFTWARE: PatentIn version 3.1
 43 <210> SEQ ID NO: 1
 45 <211> LENGTH: 15
 47 <212> TYPE: PRT
 49 <213> ORGANISM: Artificial Sequence
 53 <220> FEATURE:
 55 <223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody
 58 <220> FEATURE:
 60 <221> NAME/KEY: MISC_FEATURE
 62 <222> LOCATION: (1)..(1)
 64 <223> OTHER INFORMATION: May be any Amino Acid
 68 <400> SEQUENCE: 1
 70 Xaa Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val
 71 1 5 10 15
 75 <210> SEQ ID NO: 2
 77 <211> LENGTH: 5
 79 <212> TYPE: PRT
 81 <213> ORGANISM: Artificial Sequence
 85 <220> FEATURE:
 87 <223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody
 91 <400> SEQUENCE: 2
 93 Asp Ile Gln Met Thr
 94 1 5
 98 <210> SEQ ID NO: 3
 100 <211> LENGTH: 15
 102 <212> TYPE: PRT
 104 <213> ORGANISM: Artificial Sequence
 108 <220> FEATURE:
 110 <223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody
 113 <220> FEATURE:
 115 <221> NAME/KEY: MISC_FEATURE
 117 <222> LOCATION: (1)..(1)
 119 <223> OTHER INFORMATION: May be any Amino Acid

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/977,283A

DATE: 02/12/2002
TIME: 10:55:02

Input Set : A:\PTO.AMC.txt
Output Set: N:\CRF3\02122002\I977283A.raw

123 <400> SEQUENCE: 3
 ✓--> 125 Xaa Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val
 126 1 5 10 15
 130 <210> SEQ ID NO: 4
 132 <211> LENGTH: 381
 134 <212> TYPE: DNA
 136 <213> ORGANISM: Artificial Sequence
 140 <220> FEATURE:
 142 <223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody
 146 <220> FEATURE:
 148 <221> NAME/KEY: CDS
 150 <222> LOCATION: (1)..(381)
 152 <223> OTHER INFORMATION:
 156 <220> FEATURE:
 158 <221> NAME/KEY: sig_peptide
 160 <222> LOCATION: (1)..(60)
 162 <223> OTHER INFORMATION:
 166 <220> FEATURE:
 168 <221> NAME/KEY: MISC_FEATURE
 170 <222> LOCATION: (-12)..(-12)
 172 <223> OTHER INFORMATION: May be either Gly or Ala
 176 <400> SEQUENCE: 4
 ✓--> 177 atg agt gtg ctc act cag gtc ctg gsg ttg ctg ctg tgg ctt aca 48
 178 Met Ser Val Leu Thr Gln Val Leu Xaa Leu Leu Leu Trp Leu Thr
 179 -20 -15 -10 -5
 181 ggt gcc aga tgt gac atc cag atg act cag tct cca gcc tcc cta tct 96
 182 Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser
 183 1 5 10
 185 gca tct gtg gga gaa act gtc acc atc aca tgt cga gca agt ggg aat 144
 186 Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn
 187 15 20 25
 189 att cac aat tat tta gca tgg tat cag cag aaa cag gga aaa tct cct 192
 190 Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro
 191 30 35 40
 193 cag ctc ctg gtc tat aat gca aaa acc tta gca gat ggt gtg cca tca 240
 194 Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
 195 45 50 55 60
 197 agg ttc agt ggc agt gga tca gga aca caa ttt tct ctc agg atc aac 288
 198 Arg Phe Ser Gly Ser Gly Thr Gln Phe Ser Leu Arg Ile Asn
 199 65 70 75
 201 agc ctg cag cct gaa gat ttt ggg agt cat tac tgtcaa cat ttt tgg 336
 202 Ser Leu Gln Pro Glu Asp Phe Gly Ser His Tyr Cys Gln His Phe Trp
 203 80 85 90
 205 acc act ccg tgg acg ttc ggt gga ggc acc aag ctg gaa atc aaa 381
 206 Thr Thr Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys
 207 95 100 105
 211 <210> SEQ ID NO: 5
 213 <211> LENGTH: 127
 215 <212> TYPE: PRT

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/977,283A

DATE: 02/12/2002
TIME: 10:55:02

Input Set : A:\PTO.AMC.txt
Output Set: N:\CRF3\02122002\I977283A.raw

217 <213> ORGANISM: Artificial Sequence
 221 <220> FEATURE:
 223 <223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody
 227 <220> FEATURE:
 229 <221> NAME/KEY: MISC_FEATURE
 231 <222> LOCATION: (-12)..(-12)
 233 <223> OTHER INFORMATION: May be either Gly or Ala
 238 <400> SEQUENCE: 5
 240 Met Ser Val Leu Thr Gln Val Leu Xaa Leu Leu Leu Trp Leu Thr
 241 -20 -15 -10 -5
 244 Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser
 245 1 5 10
 248 Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn
 249 15 20 25
 252 Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro
 253 30 35 40
 256 Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
 257 45 50 55 60
 260 Arg Phe Ser Gly Ser Gly Thr Gln Phe Ser Leu Arg Ile Asn
 261 65 70 75
 264 Ser Leu Gln Pro Glu Asp Phe Gly Ser His Tyr Cys Gln His Phe Trp
 265 80 85 90
 268 Thr Thr Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys
 269 95 100 105
 272 <210> SEQ ID NO: 6
 274 <211> LENGTH: 381
 276 <212> TYPE: DNA
 278 <213> ORGANISM: Artificial Sequence
 282 <220> FEATURE:
 284 <223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody
 288 <220> FEATURE:
 290 <221> NAME/KEY: CDS
 292 <222> LOCATION: (1)..(381)
 294 <223> OTHER INFORMATION:
 298 <220> FEATURE:
 300 <221> NAME/KEY: sig_peptide
 302 <222> LOCATION: (1)..(60)
 304 <223> OTHER INFORMATION:
 308 <400> SEQUENCE: 6
 309 atg agt gtg ctc act cag gtc ctg ggg ttg ctg ctg tgg ctt aca 48
 310 Met Ser Val Leu Thr Gln Val Leu Gly Leu Leu Leu Leu Trp Leu Thr
 311 -20 -15 -10 -5
 314 ggt gcc aga tgt gac atc cag atg act cag tct cca gcc tcc cta tct 96
 315 Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser
 316 1 5 10
 318 gca tct gtg gga gaa act gtc acc gtc aca tgt cga gca agt ggg aat 144
 319 Ala Ser Val Gly Glu Thr Val Thr Val Thr Cys Arg Ala Ser Gly Asn
 320 15 20 25
 322 att cac aat tat tta gca tgg tat cag cag aaa cag gga aaa tot cct 192

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/977,283A

DATE: 02/12/2002
TIME: 10:55:02

Input Set : A:\PTO.AMC.txt
Output Set: N:\CRF3\02122002\I977283A.raw

323	Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro			
324	30	35	40	
326	cag ctc ctg gtc tat aat gca aga acc tta gca gat ggt gtg cca tca	240		
327	Gln Leu Leu Val Tyr Asn Ala Arg Thr Leu Ala Asp Gly Val Pro Ser			
328	45	50	55	60
330	agg ttc agt ggc agt gga tca gga aca caa tat tct ctc aag atc aac	288		
331	Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn			
332	65	70	75	
334	agc ctg cag cct gaa gat ttt ggg agt tat tac tgt caa cat ttt tgg	336		
335	Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp			
336	80	85	90	
338	agt aat ccg tgg acg ttc ggt gga ggc acc aag ctg gaa atc aaa	381		
339	Ser Asn Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys			
340	95	100	105	
344	<210> SEQ ID NO: 7			
346	<211> LENGTH: 127			
348	<212> TYPE: PRT			
350	<213> ORGANISM: Artificial Sequence			
354	<220> FEATURE:			
356	<223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody			
360	<400> SEQUENCE: 7			
362	Met Ser Val Leu Thr Gln Val Leu Gly Leu Leu Leu Leu Trp Leu Thr			
363	-20	-15	-10	-5
366	Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser			
367	1	5	10	
370	Ala Ser Val Gly Glu Thr Val Thr Val Thr Cys Arg Ala Ser Gly Asn			
371	15	20	25	
374	Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro			
375	30	35	40	
378	Gln Leu Leu Val Tyr Asn Ala Arg Thr Leu Ala Asp Gly Val Pro Ser			
379	45	50	55	60
382	Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn			
383	65	70	75	
386	Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp			
387	80	85	90	
390	Ser Asn Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys			
391	95	100	105	
395	<210> SEQ ID NO: 8			
397	<211> LENGTH: 381			
399	<212> TYPE: DNA			
401	<213> ORGANISM: Artificial Sequence			
405	<220> FEATURE:			
407	<223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody			
411	<220> FEATURE:			
413	<221> NAME/KEY: CDS			
415	<222> LOCATION: (1)..(381)			
417	<223> OTHER INFORMATION:			
421	<220> FEATURE:			
423	<221> NAME/KEY: sig_peptide			

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/977,283A

DATE: 02/12/2002
TIME: 10:55:02

Input Set : A:\PTO.AMC.txt
Output Set: N:\Crf3\02122002\I977283A.raw

425 <222> LOCATION: (1)..(60)
 427 <223> OTHER INFORMATION:
 431 <400> SEQUENCE: 8
 432 atg agt gtg ctc act cag gtc ctg gcg ttg ctg ctg tgg ctt aca 48
 433 Met Ser Val Leu Thr Gln Val Leu Ala Leu Leu Leu Trp Leu Thr
 434 -20 -15 -10 -5
 437 ggt gcc aga tgt gac atc cag atg act cag tct cca gcc tcc cta tct 96
 438 Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser
 439 1 5 10
 441 gca tct gtg gga gaa act gtc acc atc aca tgt cga gca agt ggg aat 144
 442 Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn
 443 15 20 25
 445 att cac aat tat tta gca tgg tat cag cag aaa cag gga aaa tct cct 192
 446 Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro
 447 30 35 40
 449 caa ctc ctg gtc tat aat gca aaa acc tta gca gat ggt gtg cca tca 240
 450 Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
 451 45 50 55 60
 453 agg ttc agt ggc agt gga tca gga aca caa ttt tct ctc aag atc aac 288
 454 Arg Phe Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn
 455 65 70 75
 457 agc ctg cag cct gaa gat ttt ggg agt cat tac tgtcaa cat ttt tgg 336
 458 Ser Leu Gln Pro Glu Asp Phe Gly Ser His Tyr Cys Gln His Phe Trp
 459 80 85 90
 461 acc act ccg tgg acg ttc ggt gga ggc acc aag ctg gaa atc aaa 381
 462 Thr Thr Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys
 463 95 100 105
 467 <210> SEQ ID NO: 9
 469 <211> LENGTH: 127
 471 <212> TYPE: PRT
 473 <213> ORGANISM: Artificial Sequence
 477 <220> FEATURE:
 479 <223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody
 483 <400> SEQUENCE: 9
 485 Met Ser Val Leu Thr Gln Val Leu Ala Leu Leu Leu Leu Trp Leu Thr
 486 -20 -15 -10 -5
 489 Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser
 490 1 5 10
 493 Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn
 494 15 20 25
 497 Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro
 498 30 35 40
 501 Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
 502 45 50 55 60
 505 Arg Phe Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn
 506 65 70 75
 509 Ser Leu Gln Pro Glu Asp Phe Gly Ser His Tyr Cys Gln His Phe Trp
 510 80 85 90
 513 Thr Thr Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys

Use of n and/or Xaa has been detected in the Sequence Listing.
 Review the Sequence Listing to insure a corresponding
 explanation is presented in the <220> to <223> fields of
 each sequence using n or Xaa.

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/977,283A

DATE: 02/12/2002
TIME: 10:55:03

Input Set : A:\PTO.AMC.txt
Output Set: N:\CRF3\02122002\I977283A.raw

L:70 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:125 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:178 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:240 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:575 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:650 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:744 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
L:817 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13
L:912 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14
L:917 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:14
L:921 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:14
L:925 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:14
L:929 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:14
L:933 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:14
L:937 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:14
L:941 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:14
L:945 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:14
L:988 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15
L:1442 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:1472 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:2715 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:75
L:2723 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:75
L:2727 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:75
L:2731 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:75
L:2784 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:76
L:2953 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:77
L:2957 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:77
L:2965 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:77
L:2969 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:77
L:2973 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:77
L:3100 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:78
L:3116 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:78
L:3120 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:78
L:3245 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:79
L:3253 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:79
L:3257 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:79
L:3261 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:79
L:3344 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:80
L:3356 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:80
L:3360 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:80
L:3589 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:81
L:3593 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:81
L:3597 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:81
L:3601 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:81
L:3605 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:81
L:3609 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:81
L:3617 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:81